Signal transduction pathways in modulation of ciliary beat frequency by methacholine.
The release of endogenous neurotransmitters plays an important role in the airway mucosal defense system. We studied the in vitro effect of methacholine, a beta-methyl ester of acetylcholine, on the ciliary beat frequency (CBF) of human adenoid explants and its mechanism of action. Tissue explants were cultured at 35 degrees C and covered with 1.0 mL of culture medium: minimum essential Eagle's medium (MEM) containing L-arginine (1.2 x 10(-3) mol/L). Methacholine was added to the cultured tissue at concentrations of 10(-10), 10(-8), and 10(-6) mol/L. The CBF was determined by phase contrast microscopy and microphotometry. Methacholine increased CBF in a dose-dependent manner with a maximum increase of 23.0% +/- 1.8% (p < .001). Atropine (10(-6) mol/L) significantly inhibited the ciliostimulatory effects of methacholine (p < .0007). The role of endogenous prostaglandins in methacholine-induced ciliostimulation was determined by treating specimens with a cyclooxygenase inhibitor (diclofenac sodium). Diclofenac (10(-6) mol/L) significantly inhibited the ciliostimulatory effects of methacholine (p < .0007). To determine if nitric oxide (NO) acts as an intermediary in ciliostimulation by methacholine, endogenous NO production was inhibited by treating specimens with an L-arginine analog, NG-nitro-L-arginine methyl ester (L-NAME), prior to addition of methacholine. L-NAME (10(-6) mol/L) inhibited the effects of methacholine in L-arginine-free MEM (p < .008), and this inhibition was reversed by L-arginine (10(-3) mol/L). To further examine the actions of NO in methacholine-induced ciliostimulation, a cyclic guanosine 3'5'-monophosphate (cGMP) kinase inhibitor (KT-5823) was used, prior to the addition of methacholine. KT-5823 (10(-6) mol/L) significantly inhibited the effects of methacholine (p < .0001). Ciliostimulation by methacholine in human upper airway mucosa involves both prostaglandin and NO second messengers and activation of a cGMP-dependent kinase.
Yang
B
B
Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Schlosser
R J
RJ
McCaffrey
T V
TV
D000109:Acetylcholine / Q000502:physiology; D000234:Adenoids / Q000187:drug effects / Q000502:physiology; D001285:Atropine / Q000494:pharmacology; D002923:Cilia / Q000187:drug effects / Q000502:physiology*; D000242:Cyclic AMP / Q000502:physiology; D006152:Cyclic GMP / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D016210:Methacholine Chloride / Q000494:pharmacology*; D018721:Muscarinic Agonists / Q000494:pharmacology*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009297:Nasal Mucosa / Q000187:drug effects / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology; D010277:Parasympathomimetics / Q000494:pharmacology*; D011453:Prostaglandins / Q000502:physiology; D015290:Second Messenger Systems / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D010277:Parasympathomimetics; D011453:Prostaglandins; D016210:Methacholine Chloride; D009569:Nitric Oxide; D001285:Atropine; D000242:Cyclic AMP; D006152:Cyclic GMP; D000109:Acetylcholine